Scientists: Alzheimer's Treatment Needs New Approach
Why it matters: Aging populations face a pressing global health challenge as Alzheimer's disease steadily erodes memory and thinking abilities.
- Professor Yan-Jiang Wang and colleagues argue that Alzheimer's complexity, involving amyloid-beta (Aβ) buildup, Tau protein tangles, genetic risks, and aging, necessitates comprehensive treatment approaches.
- New treatments like monoclonal antibodies lecanemab and donanemab have shown some success in slowing cognitive decline but do not reverse the disease or restore normal brain function.
- Future strategies are expected to move beyond targeting only Aβ to address Tau hyperphosphorylation, genetic factors via CRISPR/Cas9, and aging-related changes with therapies like senolytics.
Scientists now believe Alzheimer's disease is a complex interplay of biology, aging, and overall health, rather than a single problem, according to a review in Science China Life Sciences. This shift in understanding suggests that current single-target treatments, like monoclonal antibodies lecanemab and donanemab, offer only modest benefits and that future strategies must be multi-pronged, encompassing gene editing, brain-cell rejuvenation, and gut health interventions.
